TY - JOUR
T1 - Equal access to innovative therapies and precision cancer care
AU - Buzyn, Agnès
AU - Blay, Jean Yves
AU - Hoog-Labouret, Natalie
AU - Jimenez, Marta
AU - Nowak, Frédérique
AU - Le Deley, Marie Cécile
AU - Pérol, David
AU - Cailliot, Christian
AU - Raynaud, Jacques
AU - Vassal, Gilles
N1 - Publisher Copyright:
© 2016 Macmillan Publishers Limited.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Patients with cancers of differing histologies that express certain biomarkers are likely to benefit from treatment with targeted therapies. However, targets can be present in malignancies other than those indicated by a drug's label, and as a result, affected patients will have no access to those potentially useful drugs. To tackle this issue, the French National Cancer Institute developed the AcSé Programme in 2013. This programme is designed to make treatment decisions or recommendations on the basis of the presence of relevant biomarkers for malignancies with no targeted therapies available and also aims to improve safety, and evaluate the efficacy of targeted drugs used outside of their approved indications. Patients across France have access to molecular testing in 28 molecular genetics centres and to targeted therapies within phase II trials provided no other trials exist in which they could reasonably be included. Trials include patients below the age of 18 if safe dosing data are available. As of January 2016, 183 French clinical sites and over 7,000 patients are participating in AcSé led trials. Proof of concept is being demonstrated through trials designed to investigate the effectiveness of crizotinib and vemurafenib in a wide variety of cancers.
AB - Patients with cancers of differing histologies that express certain biomarkers are likely to benefit from treatment with targeted therapies. However, targets can be present in malignancies other than those indicated by a drug's label, and as a result, affected patients will have no access to those potentially useful drugs. To tackle this issue, the French National Cancer Institute developed the AcSé Programme in 2013. This programme is designed to make treatment decisions or recommendations on the basis of the presence of relevant biomarkers for malignancies with no targeted therapies available and also aims to improve safety, and evaluate the efficacy of targeted drugs used outside of their approved indications. Patients across France have access to molecular testing in 28 molecular genetics centres and to targeted therapies within phase II trials provided no other trials exist in which they could reasonably be included. Trials include patients below the age of 18 if safe dosing data are available. As of January 2016, 183 French clinical sites and over 7,000 patients are participating in AcSé led trials. Proof of concept is being demonstrated through trials designed to investigate the effectiveness of crizotinib and vemurafenib in a wide variety of cancers.
UR - http://www.scopus.com/inward/record.url?scp=84961393476&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2016.31
DO - 10.1038/nrclinonc.2016.31
M3 - Review article
C2 - 27000960
AN - SCOPUS:84961393476
SN - 1759-4774
VL - 13
SP - 385
EP - 393
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 6
ER -